secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMNICELL, INC. (OMCL)
CIK:        0000926326
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000926326-24-000012
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omnicell Q1 revenues down 15% to $246M, GAAP net loss $0.34/sh; initiates wind-down of Medimat RDS
--------------------------------------------------------------------------------

- Q1 GAAP revenues $246M (-15% YoY); GAAP net loss $16M ($0.34/sh) vs loss $15M ($0.33/sh) last year.
- Non-GAAP net income $1M ($0.03/sh); non-GAAP EBITDA $11M, down from $27M in Q1 2023.
- Management commits to wind down Medimat RDS product line; expects to cut >80 employees and close Bochum, Germany facility.
- Estimated nonrecurring charges $15-20M ($10-13M cash); $1.6M impairment in Q4 2023 and $3.3M severance in Q1 2024 already recorded.
- Full-year 2024 guidance unchanged: revenues $1.045-1.120B, non-GAAP EPS $0.90-1.40, non-GAAP EBITDA $90-120M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/0000926326-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926326/000092632624000012/omcl-20240426.htm
  HTML page:      https://secwatch.observer/filing/0000926326-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer